CD274 and non-small cell lung carcinoma: Advanced non-small cell lung cancer (NSCLC) patients treated with PD-1/PD-L1 inhibitors who had lower baseline NLR had better response and longer survival than those who had higher baseline NLR [10, 13, 14].